Statement of Changes in Beneficial Ownership (4)

Date : 08/22/2019 @ 11:20PM
Source : Edgar (US Regulatory)
Stock : Sarepta Therapeutics Inc New (SRPT)
Quote : 113.68  0.0 (0.00%) @ 2:01PM

Statement of Changes in Beneficial Ownership (4)

FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Mahatme Sandesh
2. Issuer Name and Ticker or Trading Symbol

Sarepta Therapeutics, Inc. [ SRPT ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
EVP, CFO & CBO
(Last)          (First)          (Middle)

215 FIRST STREET, SUITE 415
3. Date of Earliest Transaction (MM/DD/YYYY)

8/21/2019
(Street)

CAMBRIDGE, MA 02142
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  8/21/2019    M(1)    100000  A $23.85  130179  D   
Common Stock  8/21/2019    F(1)    57465  D $101.50  72714  D   
Common Stock  8/22/2019    G(2)   V 42535  D $0.00  30179  D   
Common Stock                 12012  I  By trust 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Appreciation Right  $23.85  8/21/2019    M (1)       100000    (3) 11/5/2022  Common Stock  100000  $0.00  0  D   

Explanation of Responses:
(1)  This transaction involved the exercise of a stock appreciation right ("SAR") relating to 100,000 shares of common stock, upon which the reporting person received shares of common stock net of shares of common stock withheld as payment of the exercise price and withholding taxes.
(2)  This transaction involved a gift of shares of common stock by the reporting person to a family trust.
(3)  25% of the shares subject to the SAR vested on the first anniversary measured from November 5, 2012 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vested in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the SAR were fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Mahatme Sandesh
215 FIRST STREET, SUITE 415
CAMBRIDGE, MA 02142


EVP, CFO & CBO

Signatures
/s/ David Tyronne Howton, as Attorney-in-Fact for Sandesh Mahatme 8/22/2019
**Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart

1 Year : From Jan 2019 to Jan 2020

Click Here for more Sarepta Therapeutics Charts.

Sarepta Therapeutics (NASDAQ:SRPT)
Intraday Stock Chart

Today : Friday 24 January 2020

Click Here for more Sarepta Therapeutics Charts.

Latest SRPT Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.